What to watch with CYP2D6 and menopause?

CYP2D6 is a key drug-metabolizing enzyme relevant during menopause because it processes many commonly prescribed medications, including certain antidepressants (e.g., paroxetine, venlafaxine) and tamoxifen. Genetic variants produce different metabolizer phenotypes (poor, intermediate, extensive, ultrarapid). Menopause itself may modestly affect CYP2D6 activity due to declining estrogen, but the evidence is limited and inconsistent. Genetic testing can indicate your metabolizer type, but it does not replace clinical judgment. The strongest evidence for clinical utility exists for tamoxifen; for other drugs, the benefit is debated. Be cautious: enzyme activity is also influenced by liver health, drug interactions, and other factors. Always consult a healthcare provider before adjusting medication based on genetic results.